Esophagogastric cancer: Targeted agents
- 31 May 2010
- journal article
- review article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 36 (3), 235-248
- https://doi.org/10.1016/j.ctrv.2009.12.009
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancerBritish Journal of Cancer, 2009
- Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancerBritish Journal of Cancer, 2008
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinomaBritish Journal of Cancer, 2008
- MicroRNA expression profiles of esophageal cancerThe Journal of Thoracic and Cardiovascular Surgery, 2008
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Celecoxib for the Prevention of Sporadic Colorectal AdenomasNew England Journal of Medicine, 2006
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005